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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S189used in 5 of 6 patients, and was well tolerated. Only 1 of 5
developed citrate gap, which resolved after adjusting citrate
rate. No serious hemorrhagic events were observed. Two of 6
patients died (34%) e Case #1 due to SOS, and #5 due to
systemic CMV infection. These corresponded to the patients
with the highest FO.
Conclusions: 1. Early initiation of CVVH may be a useful
modality to prevent progressive ﬂuid overload and maintain
electrolyte and acid base balance in patients with FO and AKI
following SOS.
2. CVVH with citrate regional anticoagulation is safe and
well tolerated in patients with SOS.SCT Type PRA
(percentage)
Indication for
Treatment
Patient 1 Double umbilical
cord
13 Refractory
thrombocytopenia
without bleed
Patient 2 8/8 HLA matched
peripheral
84 Refractory
thrombocytopenia
with oropharyngeal
bleeding
Patient 3 Double umbilical
cord
100 a. Refractory
thrombocytopenia
with fever
b. Refractory
thrombocytopenia
with GI bleed279
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Background: Transplant-associated thrombotic micro-
angiopathy (TA-TMA) is a signiﬁcant complication of he-
matopoietic stem cell transplantation and poses a challenge
with diagnosis and management.
Objectives: To report a case of TA-TMA in an allogeneic bone
marrow transplant (BMT) patient and discuss diagnostic and
management challenges.
Design/Method: Case Report.
Results: Seven year old female with B-thalassemia major
who underwent 10/10 matched unrelated donor BMT. Her
conditioning regimen included Busulfan, Fludarabine,
Cyclophosphamide and ATG, graft versus host disease
(GVHD) prophylaxis included cyclosporin and short course
methotrexate. Post-transplant course was complicated by
grade II acute GVHD, intracranial bleed, GI hemorrhage and
pericardial effusion. She developed several episodes of acute
kidney injury post-transplant with recovery of renal function
back to baseline creatinine (0.3-0.5 mg/dL). Six months post
transplant the patient developed hematuria and worsening
proteinuria followed by intractable hypertension. Renal
function gradually worsened with creatinine rising to w1.6
mg/dL and ended up with oliguria and ﬂuid overload. In
addition she developed hemolytic anemia, thrombocyto-
penia and peripheral blood schistocytes. Several measures
were attempted to improve her renal function including
stopping her calcineurin inhibitor, decreasing her diuretic
regimen and stopping ACE inhibition. Renal biopsy was ob-
tained and showed acute, severe thrombotic micro-
angiopathy. Complement serologies (C3, C4, CFI, CFH levels
and CFH autoantibody) were all normal or elevated. Hemo-
dialysis, therapeutic plasma exchange and basiliximab were
initiated. She received 2 doses of basiliximab and 10 treat-
ments of plasma exchange, resulting in no response. The
patient continued on thrice weekly dialysis. The patient
tolerated dialysis with great difﬁculty complicated by bilat-
eral eye pain, dizziness, extremity tingling and abdominal
pain during her treatments. Finally the patient developed a
syncopal event with mental status changes following one ofher dialysis episodes. EEG conﬁrmed seizure activity. Brain
MRI showed diffuse white matter abnormality consistent
with severe TMA. Given the patient’s progressive worsening
and extreme symptoms, Eculizumab was started. After 3
doses, she has begun to show signs of hematologic recovery
with no signs of renal recovery. Her blood pressure remains
very difﬁcult to control.
Conclusion: TA-TMA is an uncommon but signiﬁcant
complication of HSCT that presents signiﬁcant diagnostic
and management challenges. Even with accurate diagnosis
(clinically and histologically), optimal treatment strategies
remain elusive and the prognosis is poor.
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Introduction: Patients undergoing stem cell transplant
(SCT) for treatment of hematologic malignancies have often
been exposed to many blood products and may be allo-
immunized. This makes platelet transfusions less effective,
which is problematic in patients who are expected to be
profoundly thrombocytopenic for 3-4 weeks. A second-line
intervention in patients with refractory immune thrombo-
cytopenia is continuous intravenous immune globulin (IVIG)
at doses of 1 g/kg/day for 2 days and continuous platelet
transfusion (1 pack of platelets/hour for 72 hours). This
intervention has not been studied in allo-immunized SCT
patients.
Methods: A retrospective chart review was performed at the
University of Wisconsin Hospital to assess outcomes of the
continuous IVIG and platelet regimen in allo-immunized SCT
patients from 1/1/2009 to 12/31/2012. All patients also
received concurrent aminocaproic acid. Data points collected
include primary hematologic diagnosis, indication for treat-
ment, platelet response, clinical bleeding events, requirement
for further therapy, other complications during hospital stay,
and in-hospital mortality.
Results: All of the patients had an increase in platelet count
and therewere no new bleeding events during the treatment
period. The regimen does not appear to provide any long-
standing improvement in platelet response.
Discussion: Continuous IVIG and platelet transfusion does
not appear to decrease allo-reactivity as had been hoped for.
However, it does appear to be safe and does provide a
